Travere Therapeutics, Inc. (TVTX) stock intrinsic value fair value estimate & owner earnings analysis

Travere Therapeutics sells FILSPARI (sparsentan) for IgA nephropathy, a rare kidney disease, plus older tiopronin products (Thiola) for a rare kidney-stone condition. FILSPARI sales grew from $29M in 2023 to $132M in 2024 and $322M in 2025. Tiopronin sales are slowly shrinking ($88M in 2025). Total revenue was $491M in 2025, including $80M of licence and milestone income, and $297M in the first half of 2026, up about 51% on the prior year. How we measure earnings. We count cash from operations, remove working-capital swings, and subtract stock compensation as a real cost. Two judgements matter here. First, Travere pays Ligand (and Bristol-Myers Squibb) a 15-17% royalty on FILSPARI sales, and Mission a royalty on Thiola. The company books these payments as purchases of intangible assets, so they sit outside operating cash flow. We treat them as an ongoing cost of the sales, deducting $58M in 2025. Amortisation of those intangibles is added back automatically, so we deal with the fading of the older Thiola rights in the growth path rather than the earnings level. Second, the $65M pegtibatinase milestone paid in 2024 is a one-off acquisition payment and is excluded. On this basis, owner earnings per share were about -$4.59 in 2023, -$3.14 in 2024 and -$0.58 in 2025. The 2025 figure includes a one-off $40M market-access milestone from CSL Vifor; without it, about -$1.0. The business changed after FILSPARI's launch, so earlier loss-making years are not a guide, and the latest year is the only one that describes today's business. For the first half of 2026 we estimate roughly -$0.4 per share for the six months, an improvement on the prior-year half (about -$0.65). Growth check: actual owner earnings per share improved by about $2.56 in 2025, but that was a launch-year swing. We assume only about -$0.75 for 2026 and -$0.5 a year afterwards, so we do not assume the improvement continues beyond what is already in the run-rate. What is protected. FILSPARI has orphan-drug exclusivity running from February 2023 (accelerated approval) and September 2024 (full approval), i.e. to about 2030 and 2031, and a key patent (extension to January 2033 requested, not yet granted) lasts to 2030 at least. Ligand royalties run through 2033. Nothing we can name protects earnings after that. Base case (about -$2 per share). We credit the exit rate already achieved: second-quarter 2026 revenue of $170M, and drop-through of about 38% on the extra revenue over the first-half average, consistent with the swing in cash flow in the first half of 2026. We credit no further growth. Filed evidence says FILSPARI's use in FSGS (a second kidney disease) was under FDA review with a decision date of April 13, 2026, but we could not confirm the outcome from filings, so it is left out. The pipeline drug pegtibatinase is left out because it is unproven. Its cost stays in, because the company is spending on it now. On this footing owner earnings stay around -$0.5 per share a year until exclusivity ends in 2031, then fade to zero. This says the business as it stands, after heavy stock compensation, research spending and royalties, does not yet earn an owner's return. It is not a statement that the company is close to insolvency: it held $323M of cash and securities at year-end 2025 against $316M of 2.25% convertible notes due 2029. Under our method cash is not added and debt is not subtracted. Bear case (about -$6). Sales stall near the first-half 2026 level, spending on pegtibatinase and stock compensation continue (stock compensation was $38M in the first half of 2026 alone), owner earnings run about -$0.9 a year to 2031, and after exclusivity ends nothing replaces FILSPARI while costs remain. The 2029 convertible notes would need to be repaid or refinanced. That is built only from disclosed facts, but it is the negative outcome for shareholders after adding up cash burn, not a claim the company runs out of money by 2027. Bull case (about +$3). FILSPARI continues to grow at a tapering pace from a $680M exit rate, about +21% in 2027 down to +5% by 2030, using the multi-year sales record, with a further patent extension to January 2033 granted. Owner earnings turn positive in 2027-2028 and reach about $1.0 per share by 2030-2032. This still leaves out FSGS and pegtibatinase as unproven. What would make us wrong. Upside: approval of FILSPARI in FSGS, positive pegtibatinase results, or spending cuts (research and stock compensation are discretionary and could be reduced) would each raise our estimates materially, and the $40M CSL Vifor and Chugai-type milestones have proved repeatable. Downside: competing IgAN treatments or a generic challenge before 2031. First-half 2026 quarterly statements were available only as data tags, not text, so we could not read management's explanation of the second-quarter figures. Margin-of-safety price. Our cases are very wide and the base value is below zero, so price alone is not sufficient. The margin-of-safety price of about $1 per share applies only after owner earnings turn positive, a heavy discount reflecting negative downside, patent-exposed revenue and a leveraged balance sheet.